Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsZhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
Estimating the term…
The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
A substantially pure polypeptide comprising a fully human or humanized chimpanzee monoclonal antibody that binds or neutralizes anthrax edema factor (EF), wherein said monoclonal antibody comprises a heavy chain CDR1 region having an amino acid sequence of SEQ ID NO:35, a heavy chain CDR2 region having an amino acid sequence of SEQ ID NO:37, a heavy chain CDR3 region having an amino acid sequence of SEQ ID NO:39, a light chain CDR1 region having an amino acid sequence of SEQ ID NO:43, a light chain CDR2 region having an amino acid sequence of SEQ ID NO:45, and a light chain CDR3 region having an amino acid sequence of SEQ ID NO:47.
Dependencies are inferred from the claim text.